Mendus
IMMU · Nasdaq Stockholm
Public Market Listing
IMMUNasdaq Stockholm
Live quotes, historical charts, and market capitalization for Mendus are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Allogeneic dendritic cell vaccineVaccine | Acute Myeloid LeukemiaChronic Myeloid Leukemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (9)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q4 | $0 | -$3.7M | $7.0M | $4.4M | report ↗ |
View 8 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $0 | -$1.4M | $4.0M | $2.0M | report ↗ |
| 2025-Q2 | $0 | — | $6.2M | $2.4M | report ↗ |
| 2025-Q1 | $0 | — | $8.4M | $2.9M | report ↗ |
| 2024-Q4 | $0 | -$2.5M | $9.3M | $2.9M | report ↗ |
| 2024-Q3 | $0 | -$1.6M | $11M | $2.2M | report ↗ |
| 2024-Q2 | $0 | — | $12M | $3.6M | report ↗ |
| 2024-Q1 | $0 | — | $8.3M | $3.4M | report ↗ |
| 2023-Q4 | $0 | — | $12M | $3.9M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | -$8.7M | $7.0M | — | report ↗ |
Mendus reported revenue of $0M, R&D spend of $-8.69M, down 247.6% YoY, cash and equivalents of $7.03M, and a net loss of $11.57M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text